Literature DB >> 25567771

Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.

Giuseppe Mulè1, Emilio Nardi1, Laura Guarino1, Valentina Cacciatore1, Giulio Geraci1, Ilenia Calcaterra1, Bruno Oddo1, Francesco Vaccaro1, Santina Cottone1.   

Abstract

Plasma aldosterone concentrations (PACs) are often increased in the advanced stages of chronic kidney disease (CKD); however, PAC has not been fully investigated in early CKD. Moreover, little is known about the relationship between aldosteronemia and left ventricular (LV) mass in subjects with mild-to-moderate CKD. The study objectives were to analyze PAC, LV mass (LVM), LV geometry and their relationships, in a group of hypertensive patients with stage I-III CKD. One hundred ninety-five hypertensive patients with stage I-III CKD were enrolled and compared with a control group of 82 hypertensive patients without renal dysfunction. LVM was higher in subjects with CKD than in the control group and increased progressively with advancing stages of CKD (P=0.004). A similar trend was observed for PAC (P<0.0001), in which PAC was greater in CKD subjects with LV concentric geometry than in those with eccentric LV hypertrophy (P=0.01). Furthermore, in CKD patients, PAC was directly and significantly correlated with LVM (r=0.29; P<0.0001) and with relative wall thickness (RWT; r=0.36; P<0.0001). These associations remained significant even after adjustment for various confounding factors in multiple regression analyses (P<0.001). In summary, the results demonstrated that in CKD hypertensive patients, LVM, RWT and PAC are increased and related to each other from the earliest stages of renal dysfunction. Furthermore, it seems biologically plausible to speculate that aldosterone may promote a concentric geometry of the left ventricle and increase LVM in hypertensive patients with early CKD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25567771     DOI: 10.1038/hr.2014.171

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  39 in total

Review 1.  Aldosterone in chronic kidney and cardiac disease.

Authors:  Thomas H Hostetter; Hassan N Ibrahim
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

2.  Left ventricular mass in hypertensive patients with mild-to-moderate reduction of renal function.

Authors:  Giovanni Cerasola; Emilio Nardi; Giuseppe Mulè; Alessandro Palermo; Paola Cusimano; Marco Guarneri; Rosalia Arsena; Gaia Giammarresi; Anna Carola Foraci; Santina Cottone
Journal:  Nephrology (Carlton)       Date:  2010-03       Impact factor: 2.506

3.  Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.

Authors:  H Schunkert; H W Hense; M Muscholl; A Luchner; S Kürzinger; A H Danser; G A Riegger
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

4.  Hyperkalemia and hyporeninemic hypoaldosteronism.

Authors:  R A DeFronzo
Journal:  Kidney Int       Date:  1980-01       Impact factor: 10.612

5.  Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension.

Authors:  Y Shigematsu; M Hamada; M Mukai; H Matsuoka; T Sumimoto; K Hiwada
Journal:  J Hypertens       Date:  1995-01       Impact factor: 4.844

6.  Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome.

Authors:  Giuseppe Mulè; Emilio Nardi; Paola Cusimano; Santina Cottone; Giovanna Seddio; Calogero Geraci; Alessandro Palermo; Giuseppe Andronico; Giovanni Cerasola
Journal:  Am J Hypertens       Date:  2008-06-26       Impact factor: 2.689

7.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight.

Authors:  G de Simone; S R Daniels; R B Devereux; R A Meyer; M J Roman; O de Divitiis; M H Alderman
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

8.  Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension.

Authors:  Ana P C de Faria; Caroline Demacq; Valéria N Figueiredo; Carolina H Moraes; Rodrigo C Santos; Andréa R Sabbatini; Natália R Barbaro; Leandro Boer-Martins; Vanessa Fontana; Heitor Moreno
Journal:  Hypertens Res       Date:  2013-08-22       Impact factor: 3.872

9.  Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients.

Authors:  Santina Cottone; Giuseppe Mulè; Marco Guarneri; Alessandro Palermo; Maria C Lorito; Raffaella Riccobene; Rosalia Arsena; Francesco Vaccaro; Anna Vadalà; Emilio Nardi; Paola Cusimano; Giovanni Cerasola
Journal:  Nephrol Dial Transplant       Date:  2008-09-04       Impact factor: 5.992

10.  Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency.

Authors:  M Schambelan; A Sebastian; E G Biglieri
Journal:  Kidney Int       Date:  1980-01       Impact factor: 10.612

View more
  7 in total

1.  Aldosterone and abnormal left ventricular geometry in chronic kidney disease.

Authors:  Cesare Cuspidi; Marijana Tadic; Carla Sala
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

2.  Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.

Authors:  Kouichi Tamura; Ryu Kobayashi; Sona Haku; Kengo Azushima; Hiromichi Wakui
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

Review 3.  Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

Authors:  Ali Nehme; Kazem Zibara
Journal:  Hypertens Res       Date:  2017-07-06       Impact factor: 3.872

4.  The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.

Authors:  Shin-Ichiro Miura; Yasunori Suematsu; Yoshino Matsuo; Sayo Tomita; Asuka Nakayama; Masaki Goto; Tadaaki Arimura; Takashi Kuwano; Eiji Yahiro; Keijiro Saku
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

5.  Is echocardiography mandatory for patients with chronic kidney disease?

Authors:  Emilio Nardi; Giuseppe Mulè; Chiara Nardi; Giulio Geraci; Antonina Giammanco; Riccardo Bentivegna; Maurizio Averna
Journal:  Intern Emerg Med       Date:  2019-03-25       Impact factor: 3.397

Review 6.  Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities.

Authors:  Prathibha Reddy Gajjala; Maryam Sanati; Joachim Jankowski
Journal:  Front Immunol       Date:  2015-07-08       Impact factor: 7.561

7.  The relationship between Aldosterone level and various LV conditions in patients with End-stage renal disease.

Authors:  Vida Nesarhosseini; Hossein Mohsenipouya; Atieh Makhlough; Rozita Jalalian
Journal:  Caspian J Intern Med       Date:  2019
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.